Notícias

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for […]

mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.

On this episode of Stock Movers: - RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week. - Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround. - Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom.

Net loss improved 5% on international partnerships and manufacturing gains.

MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.

Moderna (NasdaqGS:MRNA) has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine targeting Bundibugyo ebolavirus. The program addresses a strain of Ebola that currently has no approved vaccine and is positioned as part of Moderna's broader infectious disease portfolio. The trial involves collaboration with CEPI and Canadian public health authorities, with a stated focus on access for low and middle income countries. This kind of targeted vaccine work highlights...

Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.

Moderna (MRNA) is back in focus after the US Food and Drug Administration approved mFLUSIVA, the company’s mRNA based flu vaccine for adults aged 50 and over, sparking renewed interest in the stock. See our latest analysis for Moderna. The FDA approval of mFLUSIVA comes after a period of sharp swings in Moderna’s share price, with a 1-month share price return down 31.23% but a year to date share price return up 82.29%. At the same time, the 1-year total shareholder return of 110.61% contrasts...

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.

Moderna stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.

Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older. The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot.

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.

News of the day for Aug. 6, 2026

Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market’s sky-high expectations.

Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.

The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.

Moderna Inc. (NASDAQ:MRNA) stock rose in Wednesday premarket trading after gaining 3.4% in the previous session, as investors reacted to the company’s latest progress in expanding its infectious disease pipeline with an investigational Ebola vaccine. Moderna Begins Phase 1 Trial For Ebola Vaccine Moderna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prevent Bundibugyo ebolavirus disease, for which no licensed vaccines currently exist. The stu

Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.

President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.

These innovative biotech companies should reap the benefits of their breakthroughs.

Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.

Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.

The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.

Moderna (MRNA) is facing several vaccine headwinds in the near to medium term, particularly for its